MX2023005846A - Composiciones para la administracion mejorada de los inhibidores de cgrp. - Google Patents

Composiciones para la administracion mejorada de los inhibidores de cgrp.

Info

Publication number
MX2023005846A
MX2023005846A MX2023005846A MX2023005846A MX2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A MX 2023005846 A MX2023005846 A MX 2023005846A
Authority
MX
Mexico
Prior art keywords
cgrp
compositions
inhibitor
improved delivery
subject
Prior art date
Application number
MX2023005846A
Other languages
English (en)
Inventor
Rajesh Kumar
Gene M Dubowchik
Charles M Conway
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of MX2023005846A publication Critical patent/MX2023005846A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2063Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporciona una composición farmacéutica que incluye un inhibidor peptídico relacionado con el gen de calcitonina (CGRP) y una cantidad que incrementa la absorción de una sustancia farmacéuticamente aceptable, tal como un carbohidrato tensioactivo. También se proporciona un método para incrementar la biodisponibilidad de un inhibidor peptídico relacionado con el gen de calcitonina (CGRP) en un sujeto, que incluye administrar vía oral para incrementar la biodisponibilidad del inhibidor de CGRP en el sujeto.
MX2023005846A 2020-11-19 2021-11-18 Composiciones para la administracion mejorada de los inhibidores de cgrp. MX2023005846A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115789P 2020-11-19 2020-11-19
US202063126550P 2020-12-17 2020-12-17
PCT/US2021/059801 WO2022109077A1 (en) 2020-11-19 2021-11-18 Compositions for improved delivery of cgrp inhibitors

Publications (1)

Publication Number Publication Date
MX2023005846A true MX2023005846A (es) 2023-06-02

Family

ID=81709748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005846A MX2023005846A (es) 2020-11-19 2021-11-18 Composiciones para la administracion mejorada de los inhibidores de cgrp.

Country Status (9)

Country Link
EP (1) EP4247364A1 (es)
JP (1) JP2023551146A (es)
KR (1) KR20230088442A (es)
AU (1) AU2021385052A1 (es)
CA (1) CA3202137A1 (es)
IL (1) IL302948A (es)
MX (1) MX2023005846A (es)
WO (1) WO2022109077A1 (es)
ZA (1) ZA202304727B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115154469A (zh) * 2022-07-22 2022-10-11 中国科学院广州生物医药与健康研究院 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
US10202435B2 (en) * 2016-04-15 2019-02-12 Alder Biopharmaceuticals, Inc. Anti-PACAP antibodies and uses thereof
BR112021011546A2 (pt) * 2019-01-20 2021-08-31 Biohaven Pharmaceutical Holding Company Ltd. Antagonistas de cgrp para tratamento de crises de enxaqueca
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
WO2021062282A1 (en) * 2019-09-25 2021-04-01 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists
CN114980862A (zh) * 2019-12-17 2022-08-30 拜尔哈文制药股份有限公司 Cgrp抑制剂的鼻内药物组合物

Also Published As

Publication number Publication date
AU2021385052A9 (en) 2024-05-02
JP2023551146A (ja) 2023-12-07
WO2022109077A1 (en) 2022-05-27
ZA202304727B (en) 2023-12-20
CA3202137A1 (en) 2022-05-27
IL302948A (en) 2023-07-01
KR20230088442A (ko) 2023-06-19
AU2021385052A1 (en) 2023-06-01
EP4247364A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
ZA202304727B (en) Compositions for improved delivery of cgrp inhibitors
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
AR048891A2 (es) Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
TR201820559T4 (tr) Azelastin içeren kompozisyonlar ve bunların kullanım metotları.
AR062320A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
CL2017003208A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
MX2022007336A (es) Composiciones farmaceuticas intranasales de inhibidores de cgrp.
TN2009000504A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
PH12021551371A1 (en) Pharmaceutical composition for the treatment of pulmonary arterial hypertension
MX2022008914A (es) Compuestos terapeuticos, formulaciones y usos de los mismos.
Choi et al. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin
MX2023007335A (es) Composiciones para la administracion mejorada de inhibidores del cgrp.
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
CO5540295A2 (es) Comprimido para tragar que comprende paracetamol
CO2021011046A2 (es) Composición farmacéutica que comprende macitentán para el tratamiento de la hipertensión pulmonar tromboembólica crónica
MX2009006699A (es) Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
EP2662077B1 (en) Effervescent compositions containing n-acetylcysteine
MX2009005218A (es) Composicion farmaceutica anticonvulsiva transnasal.
RU2010129409A (ru) Способ лечения псороптоза кроликов и отодектоза плотоядных животных
KR20110119108A (ko) 포도씨 프로안토시아니딘 추출물을 유효성분으로 함유하는 폐 섬유화증 치료 및 예방용 약학조성물
PH12015501389A1 (en) Pharmaceutical formulation of n- [5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide
US9968648B2 (en) Peptide or protein stabilizing formulation
ZA200408929B (en) Process for the preparation of pharmaceutical composition containing antiretroviral protease inhibitor with improve bioavalability
AR114587A1 (es) Formulaciones de epinefrina en aerosol
Nelson et al. Effect of faldaprevir on atazanavir pharmacokinetics in patients with HIV/HCV co-infection